Sign In Join

hgm2018 logo


HUMAN GENOME MEETING 2019

APR 24-26, 2019 | SEOUL, SOUTH KOREA

HUGO logo

Speaker

Harry Ostrer, M.D.

Albert Einstein College of Medicine, US

Harry Ostrer, M.D. is Professor of Pathology and Pediatrics at Albert Einstein College of Medicine in New York. He studies the genetic basis for disorders of sex development and other rare conditions, having recently identified the role of the signal transducing MAP kinase pathway in gonadal development. He also studies the genetic basis of prostate, breast and colorectal cancer and adverse outcomes associated with their treatment. In the diagnostic laboratory, he translates the findings of genetic discoveries into tests that can be used to identify people’s risks for having a disease prior to its occurrence or for predicting its outcome once it has occurred. Dr. Ostrer is a long-time investigator of the genetics of the Jewish people and Hispanic and Latino people. In 2007, he organized the Jewish HapMap Project, an international effort to map and sequence the genomes of Jewish people. In a series of publications about Abraham’s Children in the Genome Era, Dr. Ostrer and his team of investigators demonstrated that the history of the Jewish Diasporas could be seen in the genomes of contemporary Jewish people. In his book, Legacy: A Genetic History of the Jewish People, he explored how population genetic could affect group identity. During his recent sabbatical at the Netherlands Institute for Advanced Study, he worked on studies to analyze the population genetics of Christians, Jews and pagans from Classical Antiquity up to the Middle Ages.

Fowzan Alkuraya, M.D.

King Faisal Specialist Hospital and Research Center, Saudi Arabia

He graduated with first class honors and was the valedictorian of his class from the College of Medicine at King Saud University, Riyadh, Saudi Arabia. Dr Alkuraya completed his residency in pediatrics at Georgetown University Hospital, Washington DC, USA. He then did two fellowships in clinical genetics and molecular genetics at Harvard Medical School. He finished a postdoctoral research fellowship in the area of developmental genetics in the lab of Professor Richard Maas, also at Harvard Medical School.

Dr Alkuraya returned to Saudi Arabia in 2007 to establish the developmental genetics lab, which he still directs. He is an authority in the area of Mendelian genetics with more than 312 published manuscripts that describe his lab’s discovery of more than 200 novel disease genes in humans.

Mark Caulfield, Ph.D.

Genomics England, UK

Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension and clinical research.

In 2009 he won the Lily Prize of the British Pharmacology Society. In 2000 he established the Barts and The London Genome Centre which now underpins over 40 programmes of research. Since 2008 he directs the Barts National Institute for Health Research Cardiovascular Biomedical Research Unit.

Mark was appointed Director of the William Harvey Research Institute in 2002 and was elected a Fellow of the Academy of Medical Sciences in 2008. He led on fundraising towards the £25m William Harvey Heart Centre which created a translational clinical research centre.

Mark served on the NICE Guideline Group for hypertension and leads the Joint UK Societies’ Working Group and Consensus on Renal Denervation and was President of the British Hypertension Society (2009-2011).

In 2013 he became an NIHR Senior Investigator and was appointed as the Chief Scientist for Genomics England (NHS 100K Sequencing Project) 2013-ongoing.

Yoav Gilad, Ph.D.

The University of Chicago, US

Dr. Yoav Gilad completed his Ph.D in Molecular Genetics from the Weizmann Institute of Science in Israel in 2003, and his Post-doctoral fellowship (which was funded by EMBO) at Yale in 2005. Dr. Gilad joined the faculty of the University of Chicago at the department of Human Genetics as an Assistant Professor in 2005. He was promoted to a tenured Associate Professor in 2009, and to a Full Professor of Human Genetics in 2013. In 2016, Dr. Gilad was appointed a Professor of Medicine, and the Chief of the section of Genetic Medicine and the Vice Chair for Research at the Department of Medicine. In addition to his academic appointments, Dr. Gilad was appointed in 2010 as the Director of the Functional Genomics facility at the University of Chicago. In 2014, Dr. Gilad was appointed Chair of the Committee on Genetics, Genomics, and Systems Biology, at University of Chicago.

Sekar Kathiresan, M.D.

Broad Institute, US

I lead a human genetics research laboratory and our scientific observations have advanced understanding of the genetic basis for myocardial infarction (MI) and blood lipoproteins, led to new therapeutic targets, and defined DNA biomarkers to stratify patients at risk for MI. I have focused on: (1) gene discovery; (2) defining the mechanisms by which newly identified genes impact phenotype; and (3) using these insights to improve preventive cardiac care. In tandem with my research, I see patients in the MGH Cardiovascular Genetics Program with a focus on primary prevention of MI in individuals with a strong family history.

V.Narry Kim, Ph.D.

Seoul National University, South Korea

V. Narry Kim has made major contributions to RNA biology. She has been studying how microRNAs and mRNAs are made and regulated, and what microRNAs and mRNAs do to modulate cell signaling in cancer and embryonic stem cells. Her research group found and investigated several key factors in the microRNA pathway including Drosha, DGCR8, and Lin28, and discovered many pluripotent stem cell-specific microRNAs. More recently, Kim uncovered new gene regulatory mechanisms through RNA tailing such as uridylation and adenylation, and identified the factors and biological functions of RNA tailing.

Narry Kim currently serves as the Director of RNA Research Center at Institute for Basic Science and a Professor of Biological Sciences at Seoul National University. She received her Ph.D. in 1998 from Oxford University, UK, where she studied the functions of retroviral proteins in the construction of gene transfer vectors in the Kingsman lab. She then carried out her postdoctoral research on mRNA surveillance in the laboratory of Gideon Dreyfuss at the University of Pennsylvania, USA. She set up her own research group at Seoul National University in 2001. Narry Kim received L’Oreal-UNESCO Women in Science Award (2008), the Ho-Am Prize in Medicine (2009), the S-Oil Fellowship (2013), the Korea S&T Award (2013) and Chen Award(2017), and was elected as Foreign Associate of European Molecular Biology Organization (EMBO, 2013), Foreign Associate of National Academy of Science (NAS, 2014), and Member of Korean Academy of Science and Technology (KAST, 2014).

Guida Landouré, M.D., Ph.D.

University of Bamako, Mali

Dr. Guida Landouré is an Assistant Professor at the University of Science, Technique and Technology of Bamako (USTTB), Mali where he did his medical training before joining the National Institutes of Health (NIH) as visiting fellow from 2004 to 2007. He has a PhD from the University College London, London, UK in Neurology and Medical Genetics. Dr. Landouré is the head of the Laboratory Neurogenetics at the Faculty of Medicine and Dentistry of Bamako (USTTB), Mali working on hereditary neurological disorders including peripheral neuropathies, ataxia, myopathy and spastic paraplegia. His work has led to the characterization of new clinical entities, and the discovery and characterization of the gene for several neurological diseases. His interest goes beyond the field of neurology, and he is collaborating with other researchers on the genetics of non-syndromic hearing loss in the African population and other genetic disorders.

Jian Jun Liu, Ph.D.

Genome Institute of Singapore, Singapore

The main research interest of Prof Jianjun Liu’s lab is to understand the genetic basis of human disease inheritance and susceptibility. Mainly focusing on complex diseases, his lab pursues collaborative research to discover genetic variants that influence disease susceptibility, progression and treatment outcome by employing both candidate gene-based and genome-wide association analyses. Largely working on Asian populations, his laboratory researches on diverse disease phenotypes, including cancers, autoimmune and inflammatory diseases, neurological and psychiatric disorders, metabolic and cardiovascular diseases, and infectious diseases, which have led to the discovery of many novel susceptibility genes for human complex diseases. Prof Liu’s research also covers pharmacogenomics, particularly the discovery of biomarkers for adverse drug reactions (ADRs) in Asian populations. Recently, Prof Liu has expanded his research to population genomics, for example the SG10K project where 10,000 Singaporeans are being subjected to whole genome sequencing (WGS) analysis. Such population genomic researches are not only driving various precision medicine programs around the world to explore the application of large-scale genomic data in improving clinical and health services, but also facilitating the understanding of genetic structure of modern human populations as well as the extent and distribution of disease predisposing genetic variation in current populations as the result of a long and complicated evolutionary, migratory, and demographic history of human species.

Cai Long, Ph.D.

California Institute of Technology, US

Long Cai received his undergraduate degree at Harvard in Physics and Chemistry, working with Dudley Herschbach. He obtained his PhD at Harvard with Sunney Xie working on single molecule detection of gene expression in living cells. He conducted his postdoctoral work with Michael Elowitz at Caltech as a Beckman Fellow. He has been an assistant professor at Caltech since 2010.

Long Cai's group focuses on single cell systems biology, using super-resolution and live cell microscopy to study gene regulatory networks in cells and organisms. He has developed a novel imaging method that reveals genetic information inside cells, and is working to adapt it to identify how cells are organized in the brain, distinguish different types of hippocampal neurons, and learn how gene expression changes in the context of neurological diseases and disorders.

Nickolas Papadopoulos, Ph.D.

Johns Hopkins School of Medicine, US

Dr. Nickolas Papadopoulos is internationally known as a co‐discoverer of the genetic basis of the predisposition to hereditary nonpolyposis colon cancer (HNPCC), one of the most common hereditary forms of cancer, earlier in his career. He is known for the development of diagnostic tests and he is considered an expert in cancer genetics and diagnostics. He was part of the interdisciplinary team that was first to sequence all of the protein coding genes, determine genetic alterations and construct expression profiles of four common tumor types. Later he was involved in the identification of genetic alterations that drive tumorigenesis in multiple tumor types. Noteworthy discoveries he has made include the identification of novel mutations in chromatin remodeling genes in ovarian clear cell carcinomas and pancreatic neuroendocrine tumors. Currently, he is focused on translating the genetic information derived from cancer genome analyses to clinical applications in early detection, diagnosis and monitoring of cancer. He is a co-developer of sensitive methods for the detection of tumor DNA in liquid biopsy. He is also the co-founder of two companies that develop diagnostics for cancer.

Charles Rotimi, Ph.D.

NHGRI, US

Dr. Rotimi received his undergraduate education in biochemistry from the University of Benin in Nigeria before immigrating to the United States for further studies. He started his education in the United States at the University of Mississippi, where he obtained a master's degree in health care administration. He obtained a second master's degree and a doctorate in epidemiology from the University of Alabama at Birmingham School of Public Health. Prior to coming to the NIH, Dr. Rotimi was the director of the National Human Genome Center at Howard University.

Dr. Rotimi came to the NIH in 2008 to found the trans-institute Center for Research on Genomics and Global Health, with the mission of advancing research into the role of culture, lifestyle and genomics in disease etiology, health disparities, and variable drug response. His lab develops genetic epidemiology models and conducts epidemiologic studies that explore the patterns and determinants of common complex diseases in human populations with particular emphasis on populations of the African Diaspora. His team published the first genome-wide scan for hypertension and blood pressure in African Americans and for type-2 diabetes in West Africans. His lab contributes to the global understanding of human genetic variation by actively participating in the development of international genomic resources including the HapMap, the 1000 Genome and the African Genome Variation Project. He is on the Executive and Scientific Committee for the International Federation of Human Genetics Societies and was recently elected to the Human Genome Organization (HUGO) Council. He is the founding and past president of the African Society of Human Genetics (AfSHG).

He successfully led the establishment of the Human Heredity and Health in Africa (H3Africa) initiative with $76 million commitment from the NIH and Wellcome Trust. H3Africa will create and support network of labs that will conduct leading-edge research into the genetic and environmental determinants of diseases in Africans. He is on the editorial board of Public Health Genomics, Genome Medicine, Clinical Genetics and Journal of Applied and Translational Genomics. He is on the Coriell Personalized Medicine Collaborative Board. He was recently awarded an honorary professorship at the prestigious University of Cape Town, South Africa. He became the Chief of the Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch in 2014.

Eran Segal, Ph.D.

Weizmann Institute of Science, Israel

Eran Segal is a Professor at the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, heading a lab with a multi-disciplinary team of computational biologists and experimental scientists in the area of Computational and Systems biology. His group has extensive experience in machine learning, computational biology, probabilistic models, and analysis of heterogeneous high-throughput genomic data. His research focuses on Nutrition, Genetics, Microbiome, and Gene Regulation and their effect on health and disease. His aim is to develop personalized nutrition and personalized medicine.

Prof. Segal published over 130 publications, and received several awards and honors for his work, including the Overton prize, awarded annually by the International Society for Bioinformatics (ICSB) to one scientist for outstanding accomplishments in computational biology, and the Michael Bruno award. He was recently elected as an EMBO member and as a member of the young Israeli academy of science.

Before joining the Weizmann Institute, Prof. Segal held an independent research position at Rockefeller University, New York.

Efrat Shema, Ph.D.

Weizmann Institute of Science, Israel

My interest in chromatin biology started during my PhD in Prof. Moshe Oren’s lab at the Weizmann Institute, where I studied the roles of RNF20, a chromatin modifier, in transcription regulation and cancer. I identified RNF20 as a novel tumor suppressor in vitro and in vivo, and further elucidated its mode of action by selective regulation of gene expression. My graduate research resulted in three high profile first author publications, as well as additional publications from fruitful collaborations with labs in Israel (Yossi Shiloh, Yossi Yarden, Ashraf Brik) and abroad (Steven Johnsen, Wolfgang Fischle, Robert Roeder, Shelley Berger).

During my PhD, I was often frustrated with the limited technologies available for studying chromatin, which impede systematic and mechanistic understanding of the combinatorial action of epigenetic marks in specifying distinct biological processes. I, therefore, dedicated my postdoctoral studies in the lab of Dr. Bradley Bernstein at Massachusetts General Hospital and Harvard Medical School to develop a novel technology, based on singlemolecule imaging, for exploring the histone code. My studies yielded a number of notable biological advances, such as the identification of higher-order combinations of cooperating or opposing histone modifications whose prevalence varies with developmental potency.

In my new laboratory at the Weizmann Institute of Science, my research passion is to understand the complex network of epigenetic marks underlying chromatin behaviour and how these marks inter-relate and function in specifying distinct cell types. We strive to gain an unprecedented systematic view of the regulatory network that controls genome function, from combinatorial TF binding to the co-occurrence of epigenetic modifications and the inter-relations between these modes of regulation. I also seek to understand aberrant chromatin regulation in cancer and, in this context, how we can harness single-molecule technologies for clinical applications.

Kári Stefánsson, M.D., Dr. Med.

deCODE Genetics, Iceland

Kári Stefánsson, M.D., Dr. Med. founded deCODE in 1996. Dr. Stefánsson was a professor of Neurology, Neuropathology and Neuroscience at Harvard University and Director of Neuropathology at Beth Israel Hospital in Boston, Massachusetts from 1993-1997. From 1983 to 1993, he held faculty positions in Neurology, Neuropathology and Neurosciences at the University of Chicago. Dr. Stefánsson received his M.D. and Dr. Med. from the University of Iceland and is board-certified in neurology and neuropathology in the United States. Dr. Stefansson is recognized as a leading figure in human genetics and the man who began an approach to population genetics that is being adopted all over the world. He has shaped deCODE’s scientific approach and been actively engaged in leading its work on human genetics.

Dr. Stefánsson has received numerous awards for his work, including the Sackler Lecture at MIT (2009), the European Society of Human Genetics Award (2009), the Anders Jahre Award (2009), the American Alzheimer’s Association’s Inge Grundke-Iqbal Award (2014), and the Federation of European Biomedical Societies’ Sir Hans Krebs Medal (2016) and The American Society of Human Genetics (ASHG) has named Dr. Stefánsson the 2017 recipient of the annual William Allan Award. He has published more than 500 scientific papers.

Roser Vento, Ph.D.

Wellcome Sanger Institute, UK

Roser Vento-Tormo is an EMBO/HFSP postdoctoral fellow in Sarah Teichmann lab at the Sanger Institute, Cambridge (UK). Roser is interested in using single-cell transcriptomics to study cell-cell communication. Her work now focuses on mapping the female reproductive tissue, and studying maternal-fetal communication during pregnancy using single-cell transcriptomics.

Before coming to Cambridge, Roser Vento-Tormo did her PhD in University of Barcelona, studying the epigenetic regulation of the innate immune response. Roser earned a bachelor in biotechnology and a master in biomedical biotechnology in the Polytechnic University of Valencia.

Nic Waddell, Ph.D.

QIMR Berghofer Medical Research Institute, Australia

Dr Nic Waddell is head of the Medical Genomics group at QIMR Berghofer Medical Research Institute, Australia. She is a cancer researcher and collaborative bioinformatician who is an expert in the interpretation of next generation sequence data. Her research group focuses on the identification of mutational processes and therapeutic opportunity in cancer. She is a member of the International Cancer Genome Consortium (ICGC) and her research group has played a key role in all three Australian ICGC projects (pancreatic, ovarian and melanoma). She leads the genomics within several other cancer genome projects including oesophageal, mesothelioma and familial cancers. She has published in high impact journals such as Nature, Nature Genetics and Nature Immunology.

She has a passion for seeing genomics implemented into the clinic. She is a co-founder of genomiQa, a precision analytics company who specialise in the analysis of whole genome data. She is a member of the Australian Genomics Health Alliance (AGHA) and the Queensland Genomics Health Alliance (QGHA). Within QGHA she co-leads the ethics, legal and social working group who are developing a series of guidelines and policies to support a range of these matters including community engagement, consent and the clinical use of genomics.